Post-Filter Hematocrit for Kidney Failure

(CRRTHCT Trial)

Overseen By Benjamin R Griffin, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Gwyndolyn M. Radford

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

20 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Filter clotting is a major complication of continuous renal replacement therapy (CRRT), resulting in blood loss, reduced treatment efficacy, and increased cost. One modifiable factor associated with filter clotting is filtration fraction (FF), or the proportion of plasma water being removed from the blood over the course of the filter. In convention, a cutoff of FF\<20-30% has been used to prevent hemofilter clotting, but no evidence correlating FF with hemofilter clotting has been documented. Some experts have proposed that post-filter hematocrit (Hct) could be a more direct marker for determining hemofilter clotting risk, but evidence supporting clinical utility of this marker is lacking.

HCTpost=HCTpre/(FF(HCTpre-1)+1)

In our proposed validation study, we hope to determine whether our formula for post-filter Hct provides accurate results when compared to measured values. The information obtained from this study will potentially justify the use of utilizing the formula in future studies.

The procedure of this study is collecting blood samples from the post-filter lines of patients on CRRT at different time points and different flow rates. This will be considered the "measured post-filter hematocrit" which will then be compared to the calculated formula above, using the other values obtained from daily labs (for pre-filter hematocrit) and CRRT machine settings.

Are You a Good Fit for This Trial?

This trial is for patients experiencing filter clotting during continuous renal replacement therapy (CRRT) due to kidney failure or other renal diseases. Participants should be currently undergoing CRRT and able to provide blood samples at various times and flow rates.

Inclusion Criteria

I am 18 or older and have started on continuous renal replacement therapy.

Exclusion Criteria

Patients on ECMO

What Are the Treatments Tested in This Trial?

Interventions

• Calculated Post-Filter Hematocrit
• Measured Post-Filter Hematocrit

Trial Overview

The study aims to validate a formula for calculating post-filter hematocrit (Hct), which may indicate the risk of hemofilter clotting in CRRT. It compares calculated Hct values against actual measurements taken from patients' blood samples during treatment.

How Is the Trial Designed?

Group I: CRRT patients Experimental Treatment 2 Interventions

All participants will receive the same "intervention" of both measuring and calculating post-filter hematocrit.

Who Is Running the Clinical Trial?

Gwyndolyn M. Radford

Lead Sponsor